B. Riley Securities Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has maintained a Buy rating on Corbus Pharmaceuticals but has lowered the price target from $85 to $40.
September 20, 2024 | 5:59 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
B. Riley Securities has maintained a Buy rating on Corbus Pharmaceuticals but has lowered the price target from $85 to $40, indicating a more conservative outlook.
The maintenance of a Buy rating suggests continued confidence in Corbus Pharmaceuticals, but the significant reduction in the price target from $85 to $40 indicates a more cautious outlook on the stock's potential upside. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100